期刊
CURRENT CANCER DRUG TARGETS
卷 9, 期 7, 页码 843-853出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/156800909789760410
关键词
Osteosarcoma; ewing's sarcoma; EWS-FLI1; IGF-IR; chemotherapy; bisphosphonates
类别
资金
- Italian Association for Cancer Research
- Italian Ministry of Health
- PROTHETS
- Eurobonet
The treatment of sarcoma urgently requires new, innovative therapeutic strategies. The most recent improvements in the cure of patients with localized disease have been achieved by dose-intensification, in turn paying the price of acute severe toxicity and secondary malignancies. Keeping side-effects to a minimum is an important goal for pediatric patients and this may be achieved by combining standard cytotoxic chemotherapy with targeted approaches. In addition, after first-line therapy, very limited treatment options remain for patients with disease progression, who, like patients with metastasis at diagnosis, are in urgent need of more effective drugs. The present review highlights key examples of target identification in bone sarcomas, including chimeric oncoproteins, insulin-like growth factor receptor (IGF-IR), and tumor/microenvironment interactions. The review identifies questions and concerns that still need to be addressed before proceeding to safe clinical trials with agents against these promising new targets.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据